The developing role of metformin (Glucophage®) in the treatment of type 2 diabetes

1. Nathan DM , Buse JB , Davidson MB et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia2006;49:1711–21. and Diabetes Care 2006;29:1963-72.

2. International Diabetes Federation 2005. Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Available from www.idf.org.

3. Turner RC , Cull CA , Frighi V , Holman R. For the UKPDS Group 49. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) GroupJAMA1999;281:2005–12.

4. UKPDS Group 6 . Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res1990;13:1–11.

5. UKPDS Group 34 . Effect of intensive blood glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet1998;352:854–65.

6. Saenz A, Fernandez-Estaban I, Mataix A et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews, 2006, Issue 3.

7. Nichols GA , Alexander CM , Girman CJ et al. Treatment escalation and rise in HbA1c following successful initial metformin therapy. Diabetes Care2006;29(3):504–09.

8. ACE/AACE roadmap for the prevention and treatment of type 2 diabetes. Available on http://www.aace.com/meetings/consensus/odimplementation/roadmap.pdf

9. Donnelly LA , Doney AS , Hattersley AT , Morris AD , Pearson ER. The effect of obesity on glycaemic response to metformin or sulphonylureas in type 2 diabetes. Diabet Med2006;23:128–33.

10. Ong CR , Molyneux LM , Constantino M et al. . Long-term efficacy of metformin therapy in non-obese individuals with type 2 diabetes. Diabetes Care2006;29:2361–64.

11. Stratton IM , Adler AI , Neil AW et al. . Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ2000;321:405–12.

12. Salpeter SR , Greyber E , Pasternak G et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med2003; 163:2595–602.

13. Salpeter SR, Greyber E, Pasternak G et al. Cochrane Database of Systematic Reviews, 2006, Issue 3.

14. Jones GC , Macklin JP , Alexander WD . Contraindications to the use of metformin. BMJ2003;326:4–5.

15. Holstein A , Stumvoli M. Contraindications can damage your health—is metformin a case in point?Diabetologia2005;48:2454–9.

16. McCormack J , Kevin Johns , Hugh Tildesley Metformin's contraindications should be contraindicated. JAMC2005;173:502–04.